Myocardialbridge Bypass Graft Surgery Efficacy Verification
1 other identifier
interventional
500
1 country
1
Brief Summary
Myocardial Bridge Bypass Graft surgery is introduced to relieve the unmedical symptoms of patients with long-segment or deep myocardial bridge, clinical outcomes will be collected to verify the effectiveness of the surgery.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Jan 2020
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2020
CompletedFirst Submitted
Initial submission to the registry
February 20, 2025
CompletedFirst Posted
Study publicly available on registry
March 4, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2030
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2040
March 4, 2025
February 1, 2025
11 years
February 20, 2025
February 26, 2025
Conditions
Outcome Measures
Primary Outcomes (2)
All-Cause Mortality
Up to 240 months
Rate of counduit patency
Up to 180 months
Study Arms (3)
MyocardialBridge Bypass Graft
EXPERIMENTALThe patients with deep(depth\>2mm) and long-segement(length\>25mm) of myocardialbridge receiving myocardialbridge bypass graft surgery(MBBG)，fulfilling the following criteria: 1.presenting with pectoris angina that cannot be effectively relieved by maximum guideline-directed drug therapy; 2. No atherosclerotic plaque or merely mild atherosclerotic stenosis is detected at the proximal or entry of the myocardialbridge confirmed by coronory artery angiography.
Myocardialbridge CABG
ACTIVE COMPARATORThe patients with deep(depth\>2mm) and long-segement(length\>25mm) of myocardialbridge will be allocated to receive myocardialbridge bypass graft surgery(MBBG)，when fulfilling the following criteria: 1.presenting with pectoris angina that cannot be effectively relieved by maximum guideline-directed drug therapy; 2. The moderate-to-severe atherosclertotic stenosis is detected at the proximal or entry of the myocardialbridge confirmed by coronory artery angiography.
Myocardioalbridge Unroof
ACTIVE COMPARATORThe patients with superficial type(depth\<2mm) and short-segement(length\<25mm) of myocardial bridge will be allocated to receive "unroof" surgery，when fulfilling the following criteria: 1.presenting with pectoris angina that cannot be effectively relieved by maximum guideline-directed drug therapy; 2. No atherosclerotic plaque or merely mild atherosclerotic stenosis is detected at the proximal or entry end of the myocardialbridge confirmed by coronory artery angiography.
Interventions
The patients with deep(depth\>2mm) and long-segement(length\>25mm) of myocardialbridge receiving myocardialbridge bypass graft surgery(MBBG)，fulfilling the following criteria: 1.presenting with pectoris angina that cannot be effectively relieved by maximum guideline-directed drug therapy; 2. No atherosclerotic plaque or merely mild atherosclerotic stenosis is detected at the proximal or entry of the myocardialbridge confirmed by coronory artery angiography.
The patients with deep(depth\>2mm) and long-segement(length\>25mm) of myocardialbridge receiving myocardialbridge bypass graft surgery(MBBG)，fulfilling the following criteria: 1.presenting with pectoris angina that cannot be effectively relieved by maximum guideline-directed drug therapy; 2. The moderate-to-severe atherosclerotic stenosis is detected at the proximal or entry of the myocardialbridge confirmed by coronory artery angiography.
The patients with superficial type(depth\<2mm) and short-segement(length\<25mm) of myocardial bridge will be allocated to receive myocardialbridge "unroof" surgery，when fulfilling the following criteria: 1.presenting with pectoris angina that cannot be effectively relieved by maximum guideline-directed drug therapy; 2. The MB was superficial and short confirmed by coronory artery CT angiography.
Eligibility Criteria
You may qualify if:
- Patients with myocardialbridge requiring drug therapy or surgical intervention.
You may not qualify if:
- patients with myocardialbridge not requiring drug therapy or surgical intervention, or unwilling to be enrolled for any reason
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Xi'an International Medical Center Hospital Affiliated TO Northwest University
Xi'an, Shaanxi, 710100, China
Related Publications (1)
Zhang JZ, Zhu GY, Zhang Y, Bai LJ, Wang Z. Myocardial Bridge Bypass Graft: A Novel Surgical Procedure for Extensive Myocardial Bridges. Ann Thorac Surg. 2021 Aug;112(2):e115-e117. doi: 10.1016/j.athoracsur.2020.11.055. Epub 2021 Jan 20.
PMID: 33482166BACKGROUND
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Zhen Wang, Doctorate
Xi'an International Medical Center Hospital Affiliated To Northwest University
- STUDY DIRECTOR
Jinzhou Zhang, Doctorate
Xi'an International Medical Center Hospital Affiliated To Northwest University
- STUDY CHAIR
Jinzhou Zhang, Doctorate
Xi'an International Medical Center Hospital Affiliated To Northwest University
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
February 20, 2025
First Posted
March 4, 2025
Study Start
January 1, 2020
Primary Completion (Estimated)
December 31, 2030
Study Completion (Estimated)
December 31, 2040
Last Updated
March 4, 2025
Record last verified: 2025-02